Vicky Phelan: Which cancer is she battling, and what can we learn from her ordeal?

Vicky Phelan: Which cancer

Vicky Phelan is a cervical cancer awareness advocate and an avid CervicalCheck campaigner. She was diagnosed with terminal cancer in 2018 and often shares her journey as a cancer patient through her ups and downs. 

On RTE’s Late Late Show, she shared what kept her going through all the tough times when she said, “I don’t want to die, I’m a young woman, I have young children, that’s what made me want to fight for them … You still want more, everyone wants more.” 

Her bravery goes beyond just sharing her experiences. Her High Court action against the incorrect reading of her smear test brought the CervicalCheck scandal to the forefront. 

Vicky Phelan: Which cancer

It was later found that just like her, more than  100 women had faced a similar problem.  

Ms Phelan further critiques our lack of knowledge regarding our bodies and the blind faith in the medical profession. 

She says, “…we still look at doctors as if they are all-knowing, and that is not the case… There is a lot of stuff that goes on with women’s bodies, and it is embarrassing, but you have to be able to talk about them because otherwise, you end up in a situation like me … When you know your body, don’t be afraid to ask questions about it.”

Therefore, we must have some basic medical knowledge and awareness. 

In this article, we will be doing so by elaborating on the case of Vicky Phelan, which cancer she has, her experiences, potential treatments and symptoms. 

Vicky Phelan: Which cancer does she have, and how common is it?

Vicky Phelan, which cancer she has particularly, had been a question that had been central to the media for a long time. After the misguided results from the initial tests, she discovered that she had cervical cancer. 

The vulva, vagina, womb, fallopian tubes, and ovaries form the female reproductive system. The cervix is the lower part of the uterus that connects to the vagina. 

Cervical cancer happens when the cells in the cervix region change and get infected. These abnormal cells form a lining in the cervix that grows and develops into a tumour. 

If this growth is not monitored and stopped at the initial stage, the cancer cells can spread to the other organs.

The cervix comprises of two parts, endocervix and ectocervix. The endocervix opens into the uterus above and the ectocervix is the lower opening into the vagina. The place where these two parts meet is called the transformation region.

Cervical cancer

The ectocervix cells are the skin-like cells that form the outer surface of the cervix. The most common type of cervical cancer happens when these cells become cancerous. 

According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer amongst women worldwide. A survey demonstrated that approximately 604000 new cases of cervical cancer were diagnosed globally in 2020 itself. 

The same survey also recorded 342000 deaths due to cervical cancer in 2020, out of which 90% were from low- and middle-income countries. 

In 2019, WHO also recorded 45300 deaths in India alone. Furthermore, the incidence rate for crude cervical cancer per 100000 women is 18.7 in 2020 in India. 

The cumulative risk of cervical cancer in India in 2020 is 2 percent. Unfortunately, the mortality-to-incidence ratio happens to be 0.62. This ratio indicates deaths occurring per number of cervical cancer patients diagnosed.

The data makes us understand why the case of Vicky Phelan, which cancer she had, and the journey of her treatment is significant whilst discussing the importance of basic medical awareness.

Vicky Phelan: Which cancer did her symptoms demonstrate? What are the symptoms of cervical cancer?

Unfortunately, no extreme symptom can be traced in the early stages of the development of cervical cancer. 

As cervical cancer reaches a more advanced stage, the following symptoms can be noted: 

  • Unusual vaginal bleeding may happen after intercourse, between menstruation or after menopause, or after a pelvic exam. 
  • Pelvic pain: It can be experienced at any time or during intercourse in the form of extreme pain
  • Unusual vaginal discharge: One may note a bloody or watery vaginal discharge that may be heavy or have a foul odour

It is vital for you to remember that various other diseases also can cause similar symptoms. 

To rule out cervical cancer, it is advised that you immediately consult a professional (General Practitioner) for a proper examination. 

cancer illustration - 1

The consultancy may involve an examination of the vulva (or your vagina) with the help of  a speculum a tool that helps doctors to directly look at the cervix) and a cervical smear, a gentle brush that collects cells from the cervix.  

If the results of the above tests need further investigation, you may be asked to see a specialist for more detailed tests and examination.

Vicky Phelan: Which cancer did she have, and what were its causes?

Ms Phelan first went for a smear check for cervical cancer in 2011. Her results did not show any abnormalities, so it was unclear to Vicky Phelan which cancer she had. After several check-ups, she was diagnosed with cervical cancer in 2014. 

Later in 2017, she found out that her original result was incorrect, and that had delayed her treatment and worsened her condition. 

Cervical cancer happens when the healthy cells, mainly of the exocervix undergo mutations. Mutations are genetic changes which disrupt the normal processes of the cell. Normally, cells grow multiply and die at a certain rate. 

Due to mutations, the cells can multiply faster, and their dying process gets disrupted, thus causing an imbalance. This imbalance leads to unwanted increased growth of cells.

In short, the new cells keep on growing before the old ones can die. It is this excess of cells that causes the tumour to grow. 

Anyone with a cervix (women, trans men, non-binary people, and intersex people) are can get cervical cancer. However, it is not possible to develop this cancer if the womb or the cervix has already been surgically removed as can happen due to various reasons.

While no specific cause can be detected, a certain correlation has been established between human papillomavirus (HPV) and cervical cancer. 

HPV is a common virus; it can be transmitted through:

  • Any skin-to-skin contact of the genital area
  • Sharing of sex toys Vaginal, oral or anal sex

This does not imply that everyone with HPV will develop cancer In addition to HPV, there are certain environmental and lifestyle factors that can contribute towards getting cervical cancer . These factors include:

Being under 45: This type of cancer is more common among younger people.

  • Weakened Immune System: A weak immune system (for instance, due to HIV or AIDS) makes a person more prone to the development of cervical cancer.
  • Medical History: If the person has been a prior patient of cancer (vaginal, vulval, kidney or bladder), then it increases the risk of cancer reappearing.
  • If a person has birthed multiple children or had them at an early age (under 17), it makes them more vulnerable to the chances of cervical cancer.
  • Diethylstilbestrol (DES): This is a hormonal medicine. It is noted that if this medicine is consumed by your mother while pregnant with you, it might increase your risk of cancer. 

Centre for Disease Control and Prevention, (US body), estimates that over half of the sexually active population will be carrying this virus at some point in their lives, but only some women develop cervical cancer.

According to WHO, women with HIV are six times more likely to get cervical cancer. 

Cervical cancer often develops at a slow and gradual pace. The data estimates that the virus takes over 15-20 years to develop into cancer for women with a standard immune system and 5-10 years for women with a weakened one. 

Vicky Phelan: Which cancer is easier to detect? How is cervical cancer detected?

Detecting cancer at the earliest possible stage is one of the biggest challenges of medicine. Depending on the type of cancer, the tests for each of them are different. Melanoma, the skin cancer, is one the easiest tosuspect due to its  visible symptoms. Early detection of the cancer also leads to a high survival rate.

If the results would have been accurate, early detection would’ve told Vicky Phelan which cancer she had, and her treatment could’ve been prompt This would have increased her chances of survival and improved her quality of life.

The most common and effective method to detect cervical cancer is through screening. It is advised that women have regular screening check-ups starting from the age of 21. In the UK all eligible people receive a screening invitation every 3 years between ages 25-49, and every 5 years between ages 50-65.

The screening tests looks for :

  • HPV in the cervical cells
  • If no virus is found, the person is re-invited 3-5 years later depending on their age.
  • If the virus is found but no abnormal cells have been found, a repeat test is done after 12 months to check if the virus has been cleared off by the immune system and that the cells are no more abnormal.
  • If abnormal cells are detected, further specialised tests are done to rule out any cancer transformation in these cells.

It is important to keep in mind that screening tests are not diagnostic. It cannot tell you for sure if you have cervical cancer. If abnormalities are noted during the screening, then it is advised that you proceed further with specialised tests under your doctor’s guidance. 

Vicky Phelan: Which cancer is she battling, and what are the potential treatments?

The question was finally answered for Vicky Phelan, which cancer she had when she was diagnosed with cervical cancer in 2014. She then went on to receive a range of treatments to help her fight this disease. 

The decision on the details of treatment depends on various factors. 

These factors include:

  • Type of cervical cancer
  • Size of growth
  • Location  of the cancer
  • How far it has spread

Any past medical conditions and the general health

The treatment usually includes surgery, radiotherapy or chemotherapy. Sometimes to aid the treatment procedure, targeted medicines are also included. 

Surgery is the central part of the treatment, particularly in cases of early detection. The surgery varies according to the type and growth of the cervix cancer.

For instance, if the cancer is detected in an earlier stage with a smaller size, only a part of the cervix needs to be removed via surgery. 

But in some cases, the patient has a previous history of similar cancer and no other treatment is possible. In such cases, several parts (such as the cervix, womb, ovaries and fallopian tubes, and all or parts of the bladder, bowel, vagina or rectum) ought to be removed.

Chemotherapy kills cancer cells through medicines. This is usually undertaken to:

Decrease the cancer cells before surgery

  • After radiotherapy or/and surgery to stop cancer from coming back
  • If cancer returns or has spread to other parts of the body

Radiotherapy kills cancer cells through high-energy rays. This is usually undertaken as:

  • The primary treatment: In cases when cancer has grown large or has spread a lot
  • Prevention after the surgery: It is used along with chemotherapy to reduce the chances of cancer coming back.

Vicky Phelan: Which cancer did she have, and how can it be prevented?

Before you read further, it is critical to understand that cervical cancer is not always preventable, but adequate knowledge of risk factors and red flags can help us improve our chances of early detection and hence possible cure.

If it had been known in time to Vicky Phelan, which cancer she had, her survival chances would’ve been higher.

The two most effective means to prevent cervical cancer are cervical screening and HPV vaccination.

Cancer Illustration - 2

WHO points out the disparity between the rate of cervical cancer in high-income and low-income nations. The former has fewer cases because it holds regular programmes for vaccination against HPV, screening and treatment. E.g. in the UK, the cervical screening coverage for 2019-20 was 72%, which however was lower than the efficacy standard of 75% coverage.

Screening increases the chances of being able to locate pre-cancerous cells before they spread further. 

HPV vaccination for children aged 12 to 13 protects against any cancer that might be caused by HPV and prevents genital warts. 

Other lifestyle changes that can aid in the prevention of cervical cancer are: 

Safe intercourse: Using protection through condoms can lower your risk of HPV transmission. Though it is not an entirely effective measure, it does not prevent skin-to-skin contact in genital areas. 

  • Quit Smoking: Smoking lowers the strength of your immune system. The chemicals in cigarettes are said to aid in the development of cervical cancer. 
  • Balanced Diet: Strengthening and maintaining your immune system is extremely crucial in preventing cancer.  

What is HPV Vaccine, and is it effective?

Before we address the question of vaccines, let us understand some things regarding HPV.

HPV refers to a group of common viruses and has over 100 types. Some of these viruses are called ‘high risk’ because they are linked with cancer.

For instance, 99% of patients with cervical cancer have HPV. HPV are also associated with the development of anal cancer, genital cancer, conditions like warts, and cancer of the head and neck.

The NHS, UK programme provides a two-dose vaccination against HPV, which is deemed a necessary preventive measure for cervical cancer. 

The programme provides vaccination for kids aged 12 to 13 and offers free vaccination for anyone below 25. 

According to studies by the NHS, vaccination prevents the growth of HPV for over ten years. However, women over 25 are advised to have regular cervical screening tests as a further preventive method. 

Vicky Phelan: Which cancer has the least survival rate? What are the chances of survival of patients diagnosed with cervical cancer?

The survival rate of patients varies due to multiple factors, including which type of cancer they have and what stage they are on. According to Cancer Research UK, the rate ranges from 98% for testicular cancer to 1% for some pancreatic cancer. 

Considering the case of Vicky Phelan, she said, “Four weeks ago I didn’t think I’d see Christmas, that’s how real this is for me … At this stage, I’ve been fighting this terminal part of the disease since 2018.” 

  • A study by Cancer Research UK noted England’s general estimated survival rate. The study demonstrated:
  • More than 80% of cervical cancer patients will survive over a year and more after diagnosis
  • More than 60% of cervical cancer patients will survive over five years and more after diagnosis
  • More than 50% of cervical cancer patients will survive over ten years and more after diagnosis 

Please note that one-year or five-year survival does not mean that your condition would worsen after the period. It merely shows the years you’ve survived with cancer.

Vicky Phelan had recently posted about the progress in her health. She said, “Two weeks ago, I honestly thought it would never happen, but the human body and the human spirit are AMAZING things.”

Vicky Phelan: Which cancer affects her, and how does she cope? What is life like with cervical cancer?

After her diagnosis with cervical cancer in 2014, her journey has been full of ups and downs. 

Last month in March 2022, Vicky Phelan took a break from social media to spend time with her family. She had said, “I hope that people understand. Unfortunately, my condition has become unpredictable and is impacting more and more on my everyday life.”

Even after the treatment, women who have survived cervical cancer are often plagued with the thought of cancer coming back. 

Right after the diagnosis, each facet of the patient’s life goes through a change. During these changing and challenging times, here are some strategies which can help you cope:

  • Medical Support: Before anything, be sure that you have a medical support system consisting of professionals and your loved ones.
  • Know Better: To cope and treat yourself better, learn more about your condition. Please do so by asking questions to medical health professionals that you are consulting. You can even ask someone to accompany you, as it may be a lot of information to remember at once.  
  • Practical Support: In case you are struggling with the treatment expenses, try to consult your doctor or specialist nurse regarding this. Talking it out and asking for help initially can avoid a problem for later and also decrease your stress level. 
  • Support System: It is always better to talk to someone to help you with the onslaught of mixed emotions. By talking to someone, you are sharing your burden and organising your thoughts in a better manner. 

Throughout this entire journey, resilience often becomes the key. Taking a break and focusing on your mental health is equally essential as focusing on your physical health. 

Sometimes, it did not matter to Vicky Phelan which cancer she struggled with, but what she faced during the struggle. 

She talks about her experiences of resilience and rediscovery of self when she says, “But making plans and having something to look forward to is so important because it gets you out of the bed in the morning and gives your life purpose…make(s) me remember me, the Vicky before cancer who loved nothing more than going out with her friends, to listen to live music.”

You may also like,

Actress Helen McCrory story

Manish Koirala Cancer Story

Share:

Facebook
WhatsApp
Aviral
Reviewed By : Dr. Aviral Vatsa

Social Media

Most Popular

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, notifications only about new products, updates.

Categories

On Key

Related Posts

Non-Invasive Treatment of Breast Cancer Using Histotripsy

Breast cancer is a global health challenge, with its impact felt across all corners of the world. According to the World Health Organization (WHO), breast cancer is the most frequent cancer among women, impacting 2.1 million women each year. It causes the greatest number of cancer-related deaths among women. In 2020, it is estimated that 685,000 women died from breast cancer worldwide. As the incidence of breast cancer rises, particularly in developing countries where the majority of cases are diagnosed in late stages, the need for accessible and non-invasive treatments is more pressing than ever. Histotripsy promises to be a gamechanger for the non-invasive treatment of breast cancer worldwide. In India, breast cancer has overtaken cervical cancer as the most common cancer among women. The Indian Council of Medical Research (ICMR) has reported a significant rise in cases, with breast cancer accounting for 14% of cancers in Indian women. Urban areas register a higher incidence rate than rural areas, with cities like Delhi, Mumbai, and Kolkata showing increasing numbers. Late diagnosis is a significant issue, with a majority of breast cancer patients presenting at stage 2 or later, which can limit treatment options and reduce survival rates. Globally, the advancements in histotripsy research are paving the way for its potential application in breast cancer treatment. The technology’s precision and the possibility of outpatient procedures could lead to a paradigm shift in cancer care, offering a treatment that is not only effective but also aligns with the needs and preferences of patients. The introduction of histotripsy could be particularly transformative in India, where the healthcare system is burdened by the high volume of patients and often limited resources. The non-invasive nature of histotripsy could provide a less resource-intensive treatment option, reducing the need for surgical facilities and lengthy hospital stays. This could be a game-changer for rural and underserved areas where access to surgical oncologists and specialized care is limited. For countries like India, where cultural factors often influence healthcare decisions, the ability to preserve the breast could lead to increased acceptance and adherence to treatment protocols. The Potential Impact of Histotripsy in Treating Breast Cancer In the context of breast cancer, histotripsy has been shown to effectively reduce tumor burden in both subcutaneous and orthotopic mouse models, indicating its potential for treating primary breast tumors. The immunological responses to histotripsy ablation are mediated by the release of tumor antigens and damage-associated molecular patterns (DAMPs) into the tumor microenvironment. These factors can potentiate the effects of checkpoint inhibition, even sensitizing previously resistant cancers to immunotherapy. Histotripsy has also been shown to promote local and systemic immunological responses, reducing tumor burden in breast cancer. This is achieved by lysing target tumor cells, which release tumor antigens and DAMPs into the tumor microenvironment. The immunomodulatory impact of histotripsy may be key to expanding the impact and promise of cancer immunotherapy. In addition, histotripsy has the potential to be used in combination with other cancer treatments, such as chemotherapy and immunotherapy, to enhance their effectiveness and reduce tumor burden. The immunomodulatory impact of histotripsy may also make it an attractive option for treating metastatic breast cancer, as it can promote the polarization of monocytes and macrophages to pro-anti-tumor phenotypes, reducing the magnitude of tumor-supporting immune cells within the tumor microenvironment. What Is Histotripsy? Histotripsy is a promising non-invasive, non-ionizing, non-thermal ablation modality for the treatment of breast cancer. It initiates local and systemic immunological responses, reduces tumor burden, and promotes an anti-tumor microenvironment. The immunomodulatory impact of histotripsy may be key to expanding the impact and promise of cancer immunotherapy, making it an attractive option for treating primary and metastatic breast cancer. The potential impact of histotripsy in treating breast cancer could be significant due to several key advantages: 1. Non-invasive Treatment Histotripsy’s non-invasive nature stands out as one of its most significant benefits. Traditional cancer surgeries involve incisions, which come with risks such as infection, longer hospital stays, and longer recovery periods. By using focused ultrasound waves, histotripsy can destroy cancerous tissues without making any cuts. This approach can reduce the overall stress on the patient’s body, potentially leading to quicker recovery and less physical trauma. It could be particularly advantageous for patients who are poor candidates for surgery due to other health issues. 2. Precision The accuracy of histotripsy is due to its ability to focus ultrasound waves very precisely on a target area, often with millimeter accuracy. This precision is crucial in the treatment of breast cancer, where the goal is to remove or destroy cancerous cells without damaging the surrounding healthy tissue. Such targeted therapy could lead to better preservation of breast tissue, which is important for the patient’s physical and psychological recovery, potentially improving cosmetic outcomes and reducing the need for reconstructive surgery. 3. Reduced Side Effects Conventional treatments like chemotherapy and radiation can have significant side effects because they are not able to distinguish between healthy and cancerous cells. Histotripsy’s targeted approach could minimize this issue, as the therapy focuses only on the cancerous tissues. This targeted disruption means the body may be less overwhelmed by toxins and the side effects of cell death, possibly resulting in a better quality of life during and after treatment. 4. Repeatable treatment One of the limitations of radiation therapy is that there is a maximum total dose that can be safely administered to a patient. This cap does not exist with histotripsy. Because histotripsy does not use ionizing radiation, treatments can be administered multiple times without the cumulative risks associated with radiation. This repeatability allows clinicians to adjust treatment plans based on how the cancer responds and could be especially beneficial for aggressive or recurring breast cancers. 5. Potential in Drug Delivery Research has suggested that the mechanical disruption of tumor tissues by histotripsy can increase the permeability of those tissues. This change could potentially enhance the delivery and efficacy of chemotherapy drugs by allowing higher concentrations of the drug to penetrate the tumor. Furthermore, the combination of histotripsy and

Non-Invasive Treatment of Liver Tumors: The Revolutionary Role of Histotripsy

Liver tumors, whether benign or malignant, have long been a significant health concern. Traditional treatments, while effective, often involve invasive surgical procedures that come with inherent risks and complications. For many patients, especially those with small, numerous, or strategically located tumors, surgery might not be a viable option. However with Histotripsy, a groundbreaking procedure that promises a non-invasive alternative with remarkable potential, effective non-invasive treatment liver cancer is now possible. Histotripsy is a novel medical procedure that harnesses the power of ultrasound waves to mechanically disintegrate tissue structures. Unlike other treatments that depend on heat or radiation, histotripsy utilizes the sheer force of sound waves. These waves are meticulously focused on the target tissue, leading to its fragmentation without harming the surrounding healthy tissue. The precision and non-invasive nature of histotripsy make it a beacon of hope for liver tumor patients. A Closer Look at Evidence Research has demonstrated the efficacy of histotripsy in creating safe and effective ablations in the in vivo human-scale porcine normal liver. In various studies, target liver volumes ranging from 12–60 ml were completely ablated in durations spanning 20–75 min. The results were consistent and promising: within the ablated region, there was uniform tissue disruption with no viable cells remaining. Impressively, major vessels and bile ducts remained intact. The realm of medical treatments has always been complemented by the power of visual evidence, providing clinicians, researchers, and patients with tangible proof of a procedure’s effectiveness. Magnetic Resonance Imaging (MRI) stands at the forefront of this visual exploration. The high-resolution images produced by MRI scanners offer a detailed look into the internal structures of the liver, both before and after histotripsy treatment. Specifically, axial T2-weighted MR images have been invaluable (Figure 1). These images vividly depict the ablation volume, which is the targeted area that underwent histotripsy. The clarity and precision of these images allow medical professionals to ascertain the exact boundaries of the treated area, ensuring that the tumor cells have been effectively disrupted while leaving the surrounding healthy liver tissues untouched. Complementing the MRI scans are gross morphological examinations. These examinations, often conducted post-procedure, provide a hands-on, macroscopic view of the liver. They reveal a consistent pattern of tissue disruption within the ablation zone, characterized by a lack of viable hepatocytes, which are the primary cells of the liver. This uniformity in tissue disruption is a testament to histotripsy’s precision, ensuring that the treatment is both thorough and targeted. Furthermore, the visual evidence extends beyond just the immediate aftermath of the procedure. MR images from rodent Hepatocellular Carcinoma (HCC) models, a common type of liver cancer, provide insights into the longer-term effects of histotripsy. Initial scans of these models show tumors with a hyperintense signal on T2-weighted MRI, indicating active and aggressive tumor growth. However, post-histotripsy images paint a different picture. The previously hyperintense tumors now display a T2 hypointense signal within the ablation zone, signifying successful disruption of the tumor cells. Even more promising are follow-up scans taken 12 weeks after the procedure. These images often reveal a near-total disappearance of the tumor, replaced by a small fibrous tissue zone. This transformation underscores histotripsy’s potential not just as a treatment method but as a possible path to long-term recovery. The visual evidence supporting histotripsy’s effectiveness is both compelling and comprehensive. From high-resolution MRI scans to hands-on morphological examinations, each piece of evidence builds a case for histotripsy as a revolutionary, non-invasive treatment for liver tumors. What are the benefits of Histotripsy for Liver Tumor Treatment? The Immune Response of Histotripsy Another fascinating aspect of histotripsy is its potential to induce an immune response. FACS analysis of histotripsy-ablated tumors identified significant levels of intratumoral CD8+ T cell infiltration, much higher than untreated control tumors. This suggests that histotripsy might play a role in boosting the body’s natural defenses against cancer cells. Additionally, there was a noticeable reduction in pulmonary metastases in mice treated with histotripsy compared to untreated controls. Given that bones, especially ribs, are highly reflective and absorptive for ultrasound propagation, the feasibility and safety of histotripsy through ribs were meticulously studied. The results were reassuring. Ablation zones created through full ribcage coverage were comparable to those with only overlying soft tissue. The temperature increase to ribs was minimal, ensuring no thermal damage to the ribs or surrounding tissue. However, it’s worth noting that in one paper by Smolock et al., body wall damage was reported. This was likely due to pre-focal cavitation on the ribs. But subsequent studies addressed this by adjusting the focal pressure and duty cycle, effectively eliminating such damage. In some cases, transient thrombosis in portal and hepatic veins was observed within the treatment zone, akin to outcomes from radiofrequency and microwave ablation. The long-term response to liver treatment by histotripsy has also been studied. In normal rodent models, the acellular homogenate generated by histotripsy was absorbed within a month, leaving only a minuscule fibrous region. In tumor treatment studies, tumors were completely absorbed within 7–10 weeks post-histotripsy, with no evidence of residual tumor after three months. In conclusion, Histotripsy is undeniably a game-changer in the realm of liver tumor treatments. Its non-invasive nature, combined with its precision and efficacy, makes it a promising alternative to traditional surgical interventions. As research continues and technology advances, histotripsy could very well become the gold standard for treating not just liver tumors but a plethora of other medical conditions. For patients and medical professionals alike, it heralds a future of safer, more effective, and less invasive treatment options.

Immunological Effects Of Histotripsy for Cancer Therapy

Histotripsy, a groundbreaking non-invasive ultrasonic technique, is rapidly gaining traction in the realm of cancer therapy. By harnessing the power of cavitation, histotripsy meticulously ablates targeted tissues, positioning itself as a potential successor to traditional cancer treatments. This comprehensive article seeks to unravel the intricate immunological responses instigated by histotripsy and its profound implications for cancer therapy. What is the immunological response of Histotripsy? At its core, histotripsy ablation is driven by a phenomenon known as cavitation. This intricate process involves the meticulous generation of microbubbles within the targeted tissues, culminating in their systematic breakdown. As these tissues undergo ablation, cells are fragmented into subcellular components and acellular debris. The immunological aftermath of histotripsy, irrespective of its variant – mHIFU, BH, or CCH, remains consistent, primarily due to the analogous effects they exert on the targeted tissues. While potential nuances between these sub-therapies exist, current research has yet to pinpoint significant disparities in their immunologic outcomes. How does Histotripsy decrease pro-tumor immune cells? The tumor microenvironment is a complex ecosystem comprising various cell types, signaling molecules, and extracellular matrix components. Within this intricate network, certain immune cells, often termed as pro-tumor immune cells, play a pivotal role in promoting tumor growth and metastasis. These cells, which include tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), actively suppress anti-tumor immune responses, thereby facilitating tumor progression. a. Tumor-Associated Macrophages (TAMs): TAMs are a subset of macrophages that are recruited to the tumor site and are educated by the tumor microenvironment to adopt a pro-tumor phenotype. These cells can promote tumor growth, angiogenesis, and metastasis while suppressing anti-tumor immune responses. Histotripsy’s ability to target and modulate TAMs is of significant interest. By disrupting the tumor microenvironment, histotripsy can potentially reprogram TAMs from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, thereby reversing their tumor-promoting effects. b. Myeloid-Derived Suppressor Cells (MDSCs): MDSCs are a heterogeneous group of immature myeloid cells that expand during cancer, inflammation, and infection. In the context of cancer, MDSCs play a crucial role in suppressing T cell responses and promoting tumor growth. Preliminary studies suggest that histotripsy may reduce the number and suppressive function of MDSCs in the tumor microenvironment, thereby enhancing anti-tumor immunity. c. Regulatory T cells (Tregs): Tregs are a subset of CD4+ T cells that play a critical role in maintaining immune homeostasis by suppressing excessive immune responses. However, in the tumor microenvironment, Tregs can inhibit anti-tumor immune responses, thereby facilitating tumor growth. The impact of histotripsy on Tregs is an area of active research. By disrupting the tumor microenvironment and releasing tumor antigens, histotripsy may modulate the function and recruitment of Tregs, potentially enhancing anti-tumor immunity. d. The Interplay with Other Immune Cells: Apart from the aforementioned pro-tumor immune cells, the tumor microenvironment also contains other immune cells like dendritic cells, natural killer cells, and B cells. The interplay between these cells and pro-tumor immune cells is complex and multifaceted. Histotripsy’s ability to modulate this intricate network holds immense therapeutic potential. For instance, by targeting pro-tumor immune cells, histotripsy may enhance the antigen-presenting function of dendritic cells, leading to a more robust activation of T cells and a potent anti-tumor immune response. The tumor microenvironment is a dynamic and complex landscape where various immune cells interact and influence tumor progression. Histotripsy, with its unique mechanism of action, holds the potential to modulate this environment, targeting pro-tumor immune cells, and enhancing anti-tumor immunity. As research in this area continues to evolve, a deeper understanding of histotripsy’s impact on the tumor microenvironment will pave the way for more effective and targeted cancer therapies. What is the role of Damage Associated Molecular Patterns (DAMPs)? Damage Associated Molecular Patterns (DAMPs) are a group of intracellular molecules that have garnered significant attention in the realm of immunology and cellular biology. These molecules, under normal circumstances, reside within the confines of the cell and perform essential functions. However, when cells undergo stress, trauma, or damage, DAMPs are released into the extracellular environment, where they assume a new and critical role. One of the primary functions of DAMPs upon their release is to signal the immune system of potential threats. They act as distress signals, alerting the body to the presence of damaged or dying cells. This is particularly evident in procedures like histotripsy, a non-invasive technique that mechanically disrupts tissue structures. During histotripsy, the cellular damage leads to the liberation of various DAMPs, each with its unique role in the ensuing immune response. For instance, Calreticulin (CRT) is not just a mere bystander in this process. When released, CRT moves to the cell surface, where it aids in antigen presentation. This action effectively marks the damaged cells for elimination, kickstarting an adaptive immune response tailored to address the specific threat.  High Mobility Group  is another pivotal DAMP. As a nuclear protein, its primary role within the cell is to stabilize DNA structures. However, once outside, HMGB1 becomes a potent pro-inflammatory agent. It binds to receptors on immune cells, amplifying the inflammatory response, which is crucial in situations where rapid immune action is needed. Adenosine Triphosphate (ATP), commonly recognized as the primary energy currency of the cell, also plays a role in this immune signaling process. When found outside the cell, ATP acts as a danger signal. Immune cells, recognizing the abnormal presence of extracellular ATP, are prompted to migrate to the site of injury, further intensifying the immune response. Heat Shock Proteins (HSPs) complete the ensemble of key DAMPs released during histotripsy. These proteins, typically produced in response to cellular stress, have a dual role. Inside the cell, they ensure the proper folding of proteins. However, when released, HSPs actively stimulate the immune system, further emphasizing their importance in the body’s defense mechanisms. The intricate connection between DAMPs and the immune response holds profound implications, especially in the field of oncology. Tumors, by their very nature, suppress the immune system, allowing them to grow unchecked. However, the inflammation induced by DAMPs can be harnessed and directed

Histotripsy: A Revolution in Precise Tissue Ablation

Histotripsy has emerged as a beacon of innovation in the ever-evolving landscape of medical technology. It  promises a future where precise tissue ablation can be achieved without the invasiveness of traditional surgical methods. But what makes histotripsy stand out? The answer lies in its unique mechanism of action, which harnesses the power of ultrasound to mechanically disrupt tissue structures. This article delves deep into the mechanism of histotripsy and how it paves the way for precise tissue ablation, especially in the realm of cancer treatment. What is Histotripsy? Histotripsy, a groundbreaking medical technique, is rapidly gaining traction in the healthcare sector due to its potential to revolutionise tissue ablation procedures. The term “histotripsy” is derived from the Greek words “histo,” meaning tissue, and “tripsy,” meaning to break. Histotripsy is a non-invasive approach to tissue disruption, and its unique mechanism of action  sets it apart from any other innovations. . The concept of histotripsy was first introduced at the University of Michigan in 2004. Since its inception, the technique has undergone significant advancements, with researchers continually exploring its potential applications and refining its methodology. The term itself encapsulates the essence of the procedure: a method to break down soft tissue. How does Histotripsy work? The Fundamental Mechanism: Cavitation  Cavitation, a phenomenon central to histotripsy, refers to the formation, growth, and subsequent collapse of gas or vapour-filled bubbles within a liquid medium when subjected to rapid pressure changes. In the context of histotripsy, the human body’s tissue serves as this liquid medium, and high-intensity, short-duration ultrasound pulses induce the rapid pressure changes. When tissues are exposed to these potent ultrasound pulses, the alternating high and low pressures lead to the creation of minuscule bubbles or cavities. These bubbles might initially form around pre-existing gas pockets or microscopic impurities within the tissue. As the ultrasound pulses persist, these bubbles expand due to the negative pressure phases of the ultrasound wave. Bubble Dynamics: The Heart of Tissue Disruption  The true essence of histotripsy is realised during the bubble collapse phase. Following the negative phase, the positive pressure phase of the ultrasound wave causes the expanded bubbles to undergo a swift and violent implosion. This rapid collapse generates potent local shock waves and produces high-velocity liquid jets. These intense mechanical forces, stemming from both the shock waves and the jets, act upon the surrounding tissue. The outcome is a mechanical breakdown of the tissue at a cellular level, resulting in the tissue being fractionated into a liquefied form. This liquid consists of a homogenised blend of cell debris and the extracellular matrix. How does Histotripsy achieve precision in action? In the realm of medical interventions, precision is paramount. The ability to target specific tissues or cells without affecting the surrounding structures can be the difference between successful treatment and unintended complications. Histotripsy, with its groundbreaking approach to tissue ablation, exemplifies this principle of precision in action. Let’s delve deeper into how histotripsy achieves such unparalleled accuracy. Histotripsy employs high-intensity ultrasound pulses to induce cavitation within the targeted tissue. The beauty of this technique lies in the ability to focus these ultrasound beams to a specific point, known as the focal zone. Within this focal zone, the energy of the ultrasound waves is concentrated, ensuring that the cavitation-induced tissue disruption occurs primarily within this localised area. This means that only the tissue within the focal zone is affected, while the surrounding structures remain untouched. One of the standout features that bolster histotripsy’s precision is the integration of real-time imaging. As the ultrasound waves are administered, they not only induce cavitation but also provide a live visual feed of the treatment area. This dual capability allows clinicians to monitor the formation and collapse of bubbles in real-time. Such immediate feedback ensures that the treatment is progressing as intended and allows for on-the-fly adjustments. If, for instance, the bubbles are not forming in the desired location or pattern, the clinician can instantly modify the parameters to achieve the desired effect. The precision of histotripsy can be likened to the accuracy of a surgeon’s scalpel, but without the invasiveness of a blade. The controlled generation and collapse of microbubbles ensure that only the targeted cells or tissues are disrupted. This selectivity is especially crucial when treating tumours or lesions located close to vital organs or critical structures. For example, when targeting a tumour adjacent to a major blood vessel, the precision of histotripsy ensures that the vessel remains unharmed, reducing the risk of bleeding or other complications. In many medical treatments, especially those involving radiation or surgery, there’s always a concern about collateral damage to healthy tissues. Histotripsy’s precision minimises this risk. By confining the tissue disruption to the focal zone, histotripsy ensures that the surrounding healthy tissues are spared. This not only enhances the safety profile of the treatment but also promotes faster healing and recovery. What sets Histotripsy apart from other cancer treatments? Histotripsy’s distinctive non-thermal approach to tissue ablation offers a fresh perspective in the realm of medical interventions. While many therapeutic ultrasound techniques, such as High-Intensity Focused Ultrasound (HIFU), rely on generating heat to achieve therapeutic effects, histotripsy stands apart. Traditional methods work by raising the temperature of the targeted tissue to a point where cellular proteins denature, leading to cell death. Although effective, this thermal approach has inherent risks. Elevated temperatures can inadvertently damage surrounding healthy tissues, especially if the heat spreads beyond the targeted area. Moreover, tissues sensitive to heat, like neural tissues, can be at risk of unintended damage. In contrast, histotripsy operates on a fundamentally different principle. Instead of using heat, it employs mechanical forces to achieve tissue disruption. This is achieved through the controlled generation and violent collapse of microbubbles within the tissue, a process known as cavitation. The implosive collapse of these bubbles generates intense local shock waves and produces high-speed liquid jets. These forces act on the tissue, leading to mechanical breakdown at the cellular level without the need for heat. The non-thermal nature of histotripsy offers